Home › Funds › Paulson & Co › MDGL
Paulson & Co position in MDGL
MADRIGAL PHARMACEUTICALS INC · Health Care
Paulson & Co reported holding 1,491,619 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$751.7M, representing 25.77% of its reported portfolio and ranking #1 among its reported holdings. Paulson & Co has disclosed MDGL holdings in 14 of the last 14 reported quarters, going back to Q2 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Paulson & Co's MDGL position evolved
Paulson & Co first disclosed a stake in MDGL in Q2 2023 at 350,200 shares (US$80.9M). The position peaked in Q4 2025 at 1,707,522 shares, worth US$994.4M. Across 14 filings, Paulson & Co increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,491,619 shares valued at US$751.7M — an increase of 151,599 shares quarter over quarter.. Notable position changes include a 43% increase in Q3 2023 (shares rose 58% over the following quarter), a 121% increase in Q4 2023 (shares rose 15% over the following quarter), a 61% increase in Q1 2024 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2023 | 350.20K | $80.90M | New |
| Q3 2023 | 500.00K | $73.02M | Add |
| Q4 2023 | 1.11M | $255.85M | Add |
| Q1 2024 | 1.77M | $474.00M | Add |
| Q2 2024 | 1.85M | $518.30M | Add |
| Q3 2024 | 2.04M | $392.61M | Add |
| Q4 2024 | 2.04M | $630.10M | Hold |
| Q1 2025 | 2.10M | $695.43M | Add |
| Q2 2025 | 2.09M | $632.37M | Hold |
| Q3 2025 | 1.91M | $874.90M | Reduce |
| Q4 2025 | 1.71M | $994.36M | Reduce |
| Q1 2026 | 1.39M | $728.77M | Reduce |
| Q2 2026 | 1.34M | $719.52M | Reduce |
| Q3 2026 | 1.49M | $751.72M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MDGL and 13F data
MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 39 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.08B), Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$993.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MDGL
- BAKER BROS. ADVISORS LP 2.14M sh · $1.08B · Q3 2026
- Jupiter Topco LLC 1.94M sh · $1.04B · Q2 2026
- Janus Henderson Group 1.97M sh · $993.87M · Q3 2026
- Avoro Capital Advisors LLC 1.83M sh · $923.93M · Q3 2026
- PAULSON & CO. INC. 1.49M sh · $751.72M · Q3 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 337.04K sh · $169.85M · Q3 2026
- RTW INVESTMENTS, LP 312.82K sh · $157.65M · Q3 2026
- Rock Springs Capital Management LP 177.25K sh · $89.33M · Q3 2026
- Hood River Capital Management LLC 170.68K sh · $86.02M · Q3 2026
FAQ
How long has Paulson & Co held MDGL?
Paulson & Co has disclosed MDGL holdings in 14 of the last 14 reported quarters, going back to Q2 2023.
What is Paulson & Co's current position in MDGL?
As of Q3 2026, Paulson & Co holds 1.49M shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $751.72M, representing 25.77% of its reported portfolio and ranking #1.
Has Paulson & Co been buying or selling MDGL?
In the latest 13F filing (Q3 2026), Paulson & Co increased its position in MDGL. The position peaked in Q4 2025 at 1.71M shares.
Which other funds hold MDGL?
Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, Jupiter Topco LLC, Janus Henderson Group, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.